VistaGen Therapeutics, Inc. (VTGN)
Stock Price:
$0.785 USD
-0.037 (-4.47%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $0.770 -0.014 (-1.80%) Oct 23, 7:35 PM
Key Info
| Market Cap |
44.06M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.69M |
| Shares Out |
56.16M |
| EPS (ttm) |
-0.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$0.785 |
| Previous Close |
$0.821 |
| Change ($) |
-0.037 |
| Change (%) |
-4.47% |
| Day's Open |
0.821 |
| Day's Range |
0.766 - 0.821 |
| Day's Volume |
476,068 |
| 52-Week Range |
0.294 - 1.430 |
More Stats
| Market Cap |
44.06M |
| Enterprise Value |
47.03M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.16M |
| Float |
49.56M |
| EPS (basic) |
-0.42 |
| EPS (diluted) |
-0.41 |
| FCF / Share |
-0.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.51M |
| Short Ratio |
3.35 |
| Short % of Float |
5.06% |
| Beta |
0.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
26.54 |
| Revenue |
n/a |
| Operating Income |
-17.70M |
| Net Income |
-17.69M |
| Free Cash Flow |
-13.80M |
| Net Cash |
-2.97M |
| Net Cash / Share |
-0.05 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-115.75% |
| ROE |
-653.72% |
| ROIC |
-313.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.50*
(473.61% upside)
Low
3.00
Current: $0.785
High
6.00
Target: 4.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | 1.25 | - | - | - | 0.20 | 1.34 | 2.07 |
| Revenue Growth | - | - | - | - | - | - | - | -85.07% | -35.19% | - |
| Gross Profit | - | - | - | 1.25 | - | - | - | 0.20 | 1.34 | 2.07 |
| Operating Income | -20.80 | -24.56 | -14.20 | -10.25 | -17.85 | -6.78 | -5.03 | -6.79 | -9.04 | -6.56 |
| Net Income | -20.77 | -24.59 | -14.35 | -10.26 | -47.22 | -13.89 | -2.97 | -12.89 | -12.21 | -9.48 |
| Shares Outstanding | 47.96 | 28.56 | 13.89 | 7.53 | 1.77 | 1.47 | 1.17 | 0.91 | 0.74 | - |
| Earnings Per Share | -0.50 | -0.90 | -1.12 | -1.54 | -29.08 | -10.61 | -3.81 | -25.40 | -16.60 | -36.20 |
| Operating Cash Flow | -15.76 | -14.53 | -9.06 | -7.26 | -4.81 | -2.77 | -2.13 | -3.46 | -3.57 | -0.84 |
| Capital Expenditures | - | -0.17 | - | -0.24 | -0.03 | - | -0.01 | -0.14 | -0.03 | -0.06 |
| Free Cash Flow | -15.76 | -14.70 | -9.06 | -7.50 | -4.83 | -2.77 | -2.14 | -3.60 | -3.60 | -0.90 |
| Cash & Equivalents | 1.36 | 13.10 | 10.38 | 2.92 | 0.43 | 0.07 | - | 0.64 | 0.08 | 0.14 |
| Total Debt | 4.09 | 0.07 | 0.07 | 0.07 | 0.07 | 14.26 | 6.92 | 5.35 | 3.57 | 11.80 |
| Net Cash / Debt | -2.74 | 13.03 | 10.31 | 2.85 | 0.36 | -14.19 | -6.92 | -4.71 | -3.49 | -11.66 |
| Assets | 5.77 | 14.01 | 11.28 | 3.71 | 0.99 | 0.27 | 0.26 | 0.88 | 0.34 | 0.32 |
| Liabilities | 11.50 | 6.94 | 4.36 | 3.10 | 3.97 | 20.81 | 13.06 | 13.44 | 6.05 | 18.67 |
| Book Value | -5.73 | 7.08 | 6.92 | 0.62 | -2.98 | -20.54 | -12.80 | -12.56 | -5.71 | -32.88 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
VistaGen Therapeutics, Inc. |
| Country |
United States |
| Employees |
9 |
| CEO |
Shawn K. Singh |
Stock Information
| Ticker Symbol |
VTGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VTGN |
Description
VistaGen Therapeutics, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.